May 2006
Volume 47, Issue 13
ARVO Annual Meeting Abstract  |   May 2006
Is Intravitreous Bevacizumab (Avastin) an Effective Treatment for Venous Occlusions?
Author Affiliations & Notes
  • G. Alvarez–Rivera
    Retina, Asoc, Mexico, Mexico
  • J.L. Guerrero–Naranjo
    Retina, Asoc, Mexico, Mexico
  • A. Perez–Reguera
    Retina, Asoc, Mexico, Mexico
  • D. Moreno–Paramo
    Retina, Asoc, Mexico, Mexico
  • E. Reyna
    Retina, Asoc, Mexico, Mexico
  • M. Hernandez
    Retina, Asoc, Mexico, Mexico
  • A. Solis
    Retina, Asoc, Mexico, Mexico
  • M. Abraham
    Retina, Asoc, Mexico, Mexico
  • E. Romo
    Retina, Asoc, Mexico, Mexico
  • H. Quiroz–Mercado
    Retina, Asoc, Mexico, Mexico
  • Footnotes
    Commercial Relationships  G. Alvarez–Rivera, None; J.L. Guerrero–Naranjo, None; A. Perez–Reguera, None; D. Moreno–Paramo, None; E. Reyna, None; M. Hernandez, None; A. Solis, None; M. Abraham, None; E. Romo, None; H. Quiroz–Mercado, None.
  • Footnotes
    Support  Rioarronte Foundation
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 4254. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      G. Alvarez–Rivera, J.L. Guerrero–Naranjo, A. Perez–Reguera, D. Moreno–Paramo, E. Reyna, M. Hernandez, A. Solis, M. Abraham, E. Romo, H. Quiroz–Mercado; Is Intravitreous Bevacizumab (Avastin) an Effective Treatment for Venous Occlusions? . Invest. Ophthalmol. Vis. Sci. 2006;47(13):4254.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

To evaluate visual results and macular thicknes changes measured by optical coherence tomography (OCT) in patients diagnosed with venous occlusions treated with intravitreous Bevacizumab.


A pilot study. 10 patients were include (4 with central vein occlusion and 6 with branch vein occlusion). With previous written consentiment, we performed full opthalmologic examination with biomicroscopy, best corrected visual acuity, fluorescein angiography, OCT, and measure intraocular pressure, full fisical examination including sistemic presure. After asepsia and antiseptical techniques we aplied to selected patients 0.1ml. (125mg.) intraocular bevacizumab via pars plana.


Table 1


Intravitreous bevacizumab inyection may be an efficent, safe, and low–cost treatment in patients with venous occlusions.  

Keywords: retinal neovascularization • vascular occlusion/vascular occlusive disease • retinal culture 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.